

9 May 2024

## Asthma

### 1. How many patients have been treated (for any condition) in the last 4 months with:

#### Adult Service:

- **Benralizumab** 126
- **Dupilumab** 71
- **Omalizumab** 24
- **Reslizumab** 0
- **Mepolizumab** 246
- **Tezepelumab** 14

#### Paediatric Service:

- **Benralizumab** 0 (not licensed in children)
- **Dupilumab** <5
- **Omalizumab** 0
- **Reslizumab** 0
- **Mepolizumab** <5
- **Tezepelumab** Licensed but not used

**Use of <5 (less than five):** We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act, as the small numbers involved could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018.

### 2. Of the patients treated in the last 4 months with any of the above products, please provide the number of patients by the following age-groups:

#### Adult Service:

- **Age 6 – 11** 0
- **Age 12 - 17** 0
- **Age 18 and above** All

#### Paediatric Service:

- **Age 6 - 11** <5
- **Age 12 - 17** 5
- **Age 18 and above** 0

9 May 2024

**3. How many patients have been treated in the last 4 months by the  
Respiratory Medicine department ONLY with:**

Adult Service:

- **Dupilumab** 69
- **Omalizumab** 24

Paediatric Service:

- **Dupilumab** <5
- **Omalizumab** 0